Targeting ADM or its downstream signaling pathways may therefore offer a promising therapeutic strategy to restore CD8+ T cells function and enhance anti-tumor immunity, particularly in metastatic or immunotherapy-resistant settings. The gene discussed is CD8A; the disease is neoplasm.